Calgary, Canada – The Newswire – April 2, 2024- Voyageur Pharmaceuticals Ltd (TSXV:VM) (OTC: VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, on April 2, 2024, announces it issued 1,020,055 Deferred Share Units ("DSUs") to directors of the Company pursuant to its fixed 10% equity incentive compensation plan (the "Plan").  Each DSU represents a right of the holder to receive one common share ("Common Share") of the Company effective as of the date that the holder ceases service as a director of the Company. The DSUs are used to compensate directors

Calgary, Alberta, Canada / TheNewswire / March 26, 2024 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Company"), announces that it has filed its annual audited financial statements and management's discussion and analysis for the year ended November 30, 2023 on SEDAR+.

Calgary, Alberta, Canada – TheNewswire - March 13, 2024 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Corporation"), announces a significant advancement in its partnership with Rain Cage Carbon Inc. ("Rain Cage"). This milestone signifies the execution of a royalty agreement that solidifies the exclusive development and license agreement between the parties and it further reinforces Voyageur’s commitment to pioneering sustainable carbon drug development.

Calgary, Canada – TheNewswire - March 4, 2024 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Corporation") and Applied Pharmaceutical Innovation (API), a leading industry-funded not-for-profit organization driving life sciences commercialization, proudly announce the signing of a Master Services Agreement (MSA). This collaboration represents a significant advancement in both entities’ commitment to innovation, heralding a transformative step forward for Canada’s thriving life sciences sector.

Calgary, Canada / TheNewswire / March 1, 2024 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) ("Voyageur" or the "Company"), a provider of innovative medical imaging solutions, is pleased to announce it has closed its previously announced (January 16, 2024) non-brokered private placement (the "Offering") of units ("Units") sold at a price of $0.08 per Unit.  Pursuant to the Offering, the Company issued 6,106,250 Units for total gross proceeds of $488,500.

Calgary, Canada – TheNewswire - January16, 2024 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) ("Voyageur" or the "Company"), a provider of innovative medical imaging solutions, is pleased to announce a proposed non-brokered private placement of up to 10,000,000 units ("Units") at a price of $0.08 per Unit, for gross proceeds of up to CND$800,000 (the "Offering"). Each Unit shall be comprised of one common share in the capital of the Company (each, a "Common Share"). one Common Share purchase warrant (each, a "Warrant"), each Warrant exercisable at $0.15 for twenty-four months from clo

Calgary, Canada – TheNewswire - December 21, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, on December 19, 2023, it issued 590,735 Deferred Share Units ("DSUs") to directors of the Company pursuant to its fixed 10% equity incentive compensation plan (the "Plan").  Each DSU represents a right of the holder to receive one common share ("Common Share") of the Company effective as of the date that the holder ceases service as a director of the Company. The DSUs are used to compensate directors of t

Calgary, Canada - TheNewswire - December 21, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, is excited to announce that its carbon capture and drug development partner, Rain Cage Carbon Inc. (“Rain Cage”), has successfully completed Stage 1 testing of a new molecule, metallofullerene, for the medical imaging industry. This significant milestone has major implications for the radiology market:

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to discuss the recent announcement regarding its international expansion and third-party manufacturing for barium sulfate products in the radiology market marks a significant development for the company. Voyageur has signed its first distribution deal with an international company. This is a crucial step in expanding its reach beyond Canada and tapping into global healthcare markets.

Calgary, Canada - TheNewswire - December 14, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, is pleased to announce the formalization of a pivotal sales and distribution alliance with an internationally recognized pharmaceutical distribution company in Central America. This landmark agreement marks a significant milestone in Voyageur's journey, signaling its entry into the global market.

Proactive Research Analyst Daniel Appiah speaks to Thomas Warner from the Londons studio after publishing a new research note on Canadian medical imaging contrast media company Voyageur Pharmaceuticals Ltd (TSX-V:VM) (OTC:VYYRF).

Calgary, Canada – TheNewswire - September 14, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA: VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, is pleased to announce the completion of formulation and the engineering for production processing for the dry powdered barium contrast media product HDXBaTM. HDXBaTM is an oral contrast agent for suspension used as an oral drug for use in double-contrast radiographic examinations of the esophagus, stomach, and duodenum. Voyageur has a Health Canada approved license for HDXBaTM. HDXBa has been formulate

Calgary, Alberta - TheNewswire - July 13, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the "Company" or "Voyageur") announces that on July 10, 2023, it issued 383,360 Deferred Share Units ("DSUs") to directors of the Company pursuant to its fixed 10% equity incentive compensation plan (the "Plan").  Each DSU represents a right of the holder to receive one common share ("Common Share") of the Company effective as of the date that the holder ceases service as a director of the Company. The DSUs are used to compensate directors of the Corporation for their annual retainers and ar

Calgary, Canada – TheNewswire - June 12, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA: VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, is pleased to announce the release of the white paper titled "SmoothX: A Promising New Positive Oral Contrast Agent for CT." Authored by Alec J. Megibow, MD, MPH, FACR, the white paper highlights the remarkable imaging properties of Voyageur's product, SmoothX™, emphasising its potential to optimize abdominal CT examinations and maximize patient satisfaction.

Voyageur Pharmaceuticals CEO Brent Willis joins Natalie Stoberman from the Proactive studios to discuss the successful completion of environmental and geotechnical field work assessment at its Frances Creek project site through its 100% owned subsidiary Voyageur Industrial Minerals.

Proactive research analyst John Savin speaks to Thomas Warner after publishing a new research note on Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF), a Canadian company that specialises in transforming raw materials into pharmaceutical-grade contrast agents that can be used in medical imaging. Savin gives a brief summary of the note, titled "Voyageur Pharmaceuticals: Earthly profits from contrasting media."

Calgary, AB - TheNewswire - May 31, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) ("Voyageur" or the "Corporation") announces the successful completion of environmental and geotechnical field work at its Frances Creek project site. This milestone represents a significant achievement for the Corporation and its 100% owned subsidiary, Voyageur Industrial Minerals Ltd., as it fulfills both the exploration notice of work for barite sampling from the surface vein and paves the way for future quarry permitting.

VANCOUVER, BC / ACCESSWIRE / May 24, 2023 / The Power Play by The Market Herald has announced the release of new interviews with Solar Alliance, Cleantek Industries, Voyageur Pharmaceuticals and Homerun Resources discussing their latest news.

Voyageur Pharmaceuticals CEO Brent Willis join's Proactive's Natalie Stoberman to share a significant licensing agreement with Rain Cage Carbon to develop nanocarbon-based contrast drugs for medical imaging.

Click Image To View Full Size

Calgary, AB - TheNewswire - April 28, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the "Company" or "Voyageur") announces that it has filed its interim financial statements and management's discussion and analysis for the quarter ended February 28, 2023 on SEDAR.

Voyageur Pharmaceuticals CEO Brent Willis joins Proactive's Natalie Stoberman to share the latest results from its SmoothX comparative studies.

VANCOUVER, BC / ACCESSWIRE / April 11, 2023 / The Power Play by The Market Herald has announced the release of new interviews with Luminex Resources, Voyageur Pharmaceuticals,Trillion Energy, ARway and Pan Global Resources discussing their latest news.

Calgary, Alberta – TheNewswire - April 4, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") announces that it has completed comparative studies of SmoothX® versus Readi-Cat®2% with taste test and Computed Tomography (CT) scans on patients. Results of the double-blind testing showed that SmoothX® was favoured on drinkability and taste by 75% of patients compared to the competing product. The computed tomography scans were performed by Canada Diagnostics in Calgary, Alberta and resulted in equivalent performance to the current drug.

Calgary, AB - TheNewswire - March 30, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the "Company" or "Voyageur") announces that it has filed its annual audited financial statements and management's discussion and analysis for the year ended November 30, 2022 on SEDAR.

Calgary, Alberta – TheNewswire - February 14, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") continues to advance its sales and marketing programs and is preparing to launch its first product, SmoothX™ barium sulfate CT contrast media oral suspension for the CT imaging market, in Canada.

Calgary, AB - TheNewswire - January 27, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the "Company" or "Voyageur") announces that, further to its news release dated December 2, 2022, it has issued a total of 125,322 Common Shares at a deemed price of $0.09974 per Common Share for payment of outstanding debts of $12,500 owed to former directors of the Company and the outstanding debts have now been extinguished. The Common Shares issued by the Company have a hold period of four months and one day from the date of issuance in accordance with applicable securities legislation

VANCOUVER, BC, Jan. 24, 2023 /CNW/ -

  Calgary, AB - TheNewswire - January 23, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the "Company" or "Voyageur") announces that, further to its news releases dated December 8 and 23, 2022 and January 12 and 20, 2023, the use of proceeds with respect to its increased non-brokered private placement of units of the Company ("Units") at a price of $0.07 per Unit (the "Offering"), were incorrectly totalled. The gross proceeds received by Voyageur from the Offering will be used to advance Voyageur’s project in the following order:        Commissions & Offering Costs $

  Calgary, Alberta – TheNewswire - January 20, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that, further to its news releases dated December 8 and 23, 2022 and January 12, 2023, it has completed the second and final closing of its increased non-brokered private placement of units of the Company ("Units") at a price of $0.07 per Unit (the "Offering"), issuing an aggregate of 14,570,764 Units for gross proceeds of $1,019,953.53, bringing the total number of Units issued pursuant to the Offering to 17,142,133 for total gross pr

  News Release – TheNewswire - Calgary, Alberta – January 12, 2023: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA: VYYRF) (the "Company" or "Voyageur") is pleased to announce that, further to its news releases dated December 6 and 23, 2022, and due to strong investor demand for its non-brokered private placement of units of the Company ("Units") at a price of $0.07 per Unit, it has increased the maximum size of the offering from 9,285,714 Units for gross proceeds of $650,000 to 17,142,857 Units for gross proceeds of up to $1,200,000 (the "Offering").  Each Unit is comprised of one (1) common

  News Release – Calgary, Alberta – TheNewswire - December 23, 2022: Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (the "Company" or "Voyageur") is pleased to announce that, further to its news release dated December 6, 2022, it has completed the first closing of its non-brokered private placement of up to units of the Company ("Units") for proceeds of up to CDN$650,000, with each Unit being sold at a price of $0.07 per Unit (the "Offering").  Under the first closing of the Offering, the Company issued 2,571,369 Units for aggregate gross proceeds of $179,995.93. Each Unit is compris

VANCOUVER, BC / ACCESSWIRE / December 12, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Usha Resources, Voyageur Pharmaceuticals, ARway and Surge Battery Metals discussing their latest news.

News Release – Calgary, Alberta –  TheNewswire - December 8, 2022: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the "Company" or "Voyageur") announces that it has initiated its marketing campaign to introduce SmoothX™ barium sulfate CT contrast media, to the CT Imaging market in Canada. SmoothX is a generic oral barium sulfate contrast media product, designed to assist in diagnosing disease using computed tomography (CT) scans. It works by coating the gastrointestinal track with barium sulfate, so that diseased or damaged areas become visible by the CT scan.

Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur") announces that it has issued 125,322 Deferred Share Units ("DSUs") to directors pursuant to its fixed 10% equity incentive compensation plan adopted by the Company following receipt of shareholder approval on June 28, 2021 (the "Plan"). Each DSU represents a right of the holder to receive one common share ("Common Share") of the Corporation effective as of the date that the holder ceases service as a director of the Company. The DSUs are used to compensate directors of the Corporation for their annual retainers. The DSUs do not have an exercise price but have a starting value equal to approximately $0.09974 per DSU, based on the weighted average share price for the quarter ended September 30, 2022. The DSUs are subject to the terms of the Plan and the policies of the TSX Venture Exchange (the "Exchange").

VANCOUVER, BC / ACCESSWIRE / November 29, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Trillion, Gamelancer, INEO Tech, ACME Lithium and Voyageur discussing their latest news.

Voyageur Pharmaceuticals (TSXV:VM) (OTCPink:VYYRF) has completed production of a test batch of its SmoothX™ barium sulfate CT contrast media oral suspension for the CT imaging market in Canada. This production represents a significant transition...

Calgary, Alberta – TheNewswire - November 28, 2022: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") announces completion of the production test batch of its SmoothX™ barium sulfate CT contrast media oral suspension for the CT imaging market in Canada.  This development represents a significant transition for Voyageur from the development phase to the production phase, where the focus will change to scaling up to commercially viable volumes of SmoothX to supply the Canadian imaging market. Management estimates that these two milestones will likely speed up fir

VANCOUVER, BC / ACCESSWIRE / November 1, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Tantalex, Rover Metals, Gamelancer and Voyageur discussing their latest news.

Voyageur Pharmaceuticals (TSXV:VM) (OTCPink:VYYRF) has completed the design of its carbon neutral pharmaceutical facility resulting in an accelerated revenue generation timeline for its Frances Creek barium sulfate project. The timeline for...

   Calgary, Alberta – TheNewswire - October 31, 2022: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC: VYYRF) (the "Company" or "Voyageur") announces the completion of the design of its carbon neutral pharmaceutical plant and as such has accelerated the revenue generation timeline for the Frances Creek barium sulfate project, compared to stated timeline of the SGS Canada Inc preliminary economic assessment. ACH Engineering Inc has estimated the total capital cost to be CAD $30M (excluding land). The plant is designed to process approximately 5,000 tonnes per year of Frances Creek USP (US Pharma

Voyageur Pharmaceuticals (TSXV:VM) (OTCPink:VYYRF) has signed a memorandum of understanding with Rain Cage Carbon to develop fullerene-based contrast agents. Rain Cage Carbon, a private carbon capture company located in Calgary, has a proven...

VANCOUVER, BC / ACCESSWIRE / October 24, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Else Nutrition, Silver Bullet Mines, Voyageur Pharmaceuticals, RevoluGROUP and Pelangio discussing their latest news.

Calgary, Alberta – TheNewswire - October 24, 2022 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") has signed a memorandum of understanding (MOU) with Rain Cage Carbon Inc. (RCC), to enter into a development agreement for fullerene-based contrast agents. RCC, a carbon capture company located in Calgary, Alberta, has proven technology that removes CO2 and other pollutants from hydrocarbon exhaust streams. The CO2 is converted into oxygen and carbon and creates fullerene allotropes and nanotubes that can be applied to a wide variety of products to enhance stre

Voyageur Pharmaceuticals (TSXV:VM) (OTCPink:VYYRF) has submitted a notice of work with the BC Ministry of Mines, for the removal of 2,000 tonnes of barium sulfate from its Frances Creek Project. The Frances Creek project is one of the company’s...

Calgary, Alberta – TheNewswire - September 22, 2022 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") has submitted a notice of work with the BC Ministry of Mines (BCMM), for the removal of 2,000 tonnes of barite in 2023. Upon approval from the BCMM, this sample will be used for testing on a new active pharmaceutical ingredient (API) pilot plant, that is tentatively scheduled to begin construction in 2023.  Voyageur will excavate small, 2-metre-wide surface trenches, to remove 1,000 tonnes of barite from the A zone and 1,000 tonnes from the B zone. This ton

  Calgary, Alberta –  TheNewswire - August 15th, 2022: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") has appointed Albert Deslauriers as interim CFO. Al held several senior financial positions with the Lafarge Group over a 34 year career including Vice President of Finance for Lafarge Canada. Al has a financial and general management background with major public corporations including international experience working in Paris, France. He has proven leadership skills involving managing, developing, and motivating teams to achieve their objectives. With his

Calgary, Alberta –  TheNewswire - June 16, 2022: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that, further to its news releases dated May 26 and 31, 2022, it has completed its non-brokered private placement of units of the Company ("Units") at a price of $0.10 per Unit, issuing 11,570,000 Units for aggregate gross proceeds of $1,157,000 (the "Offering"). Each Unit is comprised of one (1) common share ("Common Share") and one (1) share purchase warrant ("Warrant") of Voyageur. Each whole Warrant entitles the holder thereof to purch

Calgary, Alberta – TheNewswire - May 31, 2022: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the "Company" or "Voyageur") is pleased to announce that, further to its news release dated May 26, 2022, and due to strong investor demand for its recently announced non-brokered private placement of units of the Company ("Units") at a price of $0.10 per Unit, it has increased the maximum size of the offering from 10,000,000 Units for gross proceeds of $1,000,000 to 14,000,000 Units for gross proceeds of up to $1,300,000 (the "Offering"). The net proceeds of the Offering will be used to adva

  News Release – TheNewswire - Calgary, Alberta – May 26, 2022: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it plans to complete a non-brokered private placement of up to 10,000,000 units (the "Units") of Voyageur at a price of $0.10 per Unit for aggregate gross proceeds of up to $1,000,000 (the "Offering"). There is no minimum Offering. The Units will be comprised of one (1) common share ("Common Share") and one (1) share purchase warrant ("Warrant") of Voyageur. Each whole Warrant entitles the holder thereof to purchase one

Calgary, Alberta – TheNewswire - May 18, 2022: Voyageur Pharmaceuticals Ltd. (“Voyageur” or the “Company”) (TSXV:VM) is pleased to announce that it is progressing with its product development, regulatory pathway and material processing/manufacturing operations that could result in revenue generation in Canada this year and more importantly revenue generation in the United States early next year. Product Development As part of the product development process, Voyageur has recently completed the design and testing of the first batch runs of its smoothie product line of barium sulfate co

News Release – Calgary, Alberta – TheNewswire - May 10, 2022: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the "Company" or "Voyageur") has agreed to pay deposits for work on design of the Company's manufacturing facility and pay other existing debts in an amount of up to $100,000 through the issuance of common shares of the Company ("Common Shares") at a deemed price per share of $0.11 based on the closing price of the Common Shares at the close of trading on May 10, 2022 (the "Share Payments"). The Share Payments are subject to regulatory approval, including the approval of th

Calgary, Alberta - TheNewswire – February 24, 2022: Voyageur Pharmaceuticals Ltd. (“Voyageur” or the “Company”) (TSXV:VM) (OTC:VYYRF) is pleased to announce the filing of its Preliminary Economic Assessment (“PEA”) for the development of its Frances Creek pharmaceutical barium sulfate project (the “Project”), located in British Columbia, Canada. The PEA was initially disclosed in a news release dated January 11, 2022 and was prepared by SGS Geological Services (“SGS”). The effective date of the PEA is January 11, 2022 and the technical report relating to the PEA has been filed on SEDAR.

  Calgary, Alberta – TheNewswire - February 16, 2022 - Voyageur Pharmaceuticals Ltd. (“Voyageur” or the “Company”) (TSXV:VM) (OTC:VYYRF) is pleased to announce the completion of the NI 43-101 report, the Jubilee Mountain Property, authored by Craig Dunn, P.Geo, the effective date of February 4, 2022 (the "Report") for the Jubilee Mountain copper polymetallic project (the "Jubilee Project").  In addition, Voyageur has added a second battery mineral project and has staked ground on a prospective polymetallic area of interest named the Falcon (together with the Jubilee Project, the "Projects").

VANCOUVER, BC, Jan. 11, 2022 /CNW/ - Trading resumes in:

News Release – Calgary, Alberta - TheNewswire – January 11, 2022 - Voyageur Pharmaceuticals Ltd. (“Voyageur” or the “Company”) (TSXV:VM) is pleased to announce the results of its Preliminary Economic Assessment (“PEA”) for the development of its Frances Creek pharmaceutical barium sulfate project (the “Project”), located in British Columbia, Canada. The PEA was prepared by SGS Geological Services (“SGS”). The effective date of the PEA is January 11, 2022 and a technical report relating to the PEA will be filed on SEDAR within 45 days of this news release. All values are in Canadian dollars.

VANCOUVER, BC, Jan. 11, 2022 /CNW/ - The following issues have been halted by IIROC:

Calgary, Alberta - TheNewswire - December 6, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") has a preliminary economic assessment (PEA) on its Frances Creek project pending with SGS Canada, who have stated the first draft will be completed by mid December. There have been delays outside of management's control. Building out the mining operation and product manufacturing represents the second phase of Voyageur’s plan.

Calgary, Alberta - TheNewswire - November 8, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce the signing  of a non-binding Memorandum of  Understanding (“MOU”) with Summit Nanotech Corporation (“SNT”). The MOU proposes an agreement between Voyageur and SNT to develop a more sustainable process for the production of iodine medical products, that are used as contrast agents. The process will be developed by leveraging SNT’s award winning lithium extraction technology.  

Calgary, Alberta - TheNewswire - October 18, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC:VYYRF) (the "Company" or "Voyageur") develops, manufactures and will commercialize high-performance cost-effective imaging contrast agents for the medical radiology marketplace. Today the Company announced the completion of the formation of its Scientific Advisory Board (SAB), with the additions of two leading doctors in the radiology industry. The SAB is to support the firm’s research, clinical and product development programs. The SAB is to provide Voyageur’s management team, BOD and imaging co

Calgary, Alberta - TheNewswire - September 14, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") develops, manufactures and will commercialize high-performance cost effective imaging contrast agents for the medical radiology marketplace. Today the Company announced the formation of its Scientific Advisory Board (SAB) to support the firm’s research, clinical and product development programs. The SAB is to provide our management team, BOD and our imaging consultants Dash International with expert advice and counsel that fulfills our mission and our vision

Calgary, Alberta - TheNewswire - August 19, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") has been working with SGS Canada Inc. on the Preliminary Economic Assessment (PEA) for its Frances Creek barium Quarry operation. A critical part of the PEA is the design of an upgrading system to process the Frances Creek barium concentrate to meet the requirements of the United States Pharmacopeia (USP). The upgrading process has been the primary focus, such that the PEA could not proceed until the upgrading process is developed and verified. The final design

Calgary, Alberta – TheNewswire - August 12, 2021 – Voyageur Pharmaceuticals Ltd. (TSXV:VM) USA (OTC:VYYRF) (the "Company" or "Voyageur") announced that it has issued 200,000 options to directors pursuant to its incentive stock option plan (the “Options”). In addition, the Company announces it has issued 169,872 Deferred Share Units (“DSU’S”) to directors pursuant to its equity incentive compensation plan.

Calgary, Alberta - TheNewswire - July 26th, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”). Voyageur is very pleased to announce that Frank Wright and Ralph Hesje are being appointed to the Voyageur Board as Director’s effective immediately. Voyageur is committed to create a strong independent board of directors with extensive experience in board management, business development, business management, manufacturing & processing management, logistics, merger and acquisitions, strong backgrounds in corporate governance and ethics, and have  track rec

Calgary, Alberta - TheNewswire - June 14, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") announces that, further to news releases dated April 13 and 23, and May 5 and 28, 2021, Voyageur has closed its financing and will not be proceeding with a third and final tranche of its non-brokered private placement of common units ("Common Units") and flow-through units ("Flow-Through Units") (the "Offering"). Pursuant to the Offering, the Company issued a total of 8,173,731 Common Units for gross proceeds of $1,226,059.65 and 1,647,264 Flow-Through Units for g

Calgary, Alberta – TheNewswire - May 28, 2021 – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC:VYYRF) (the "Company" or "Voyageur") announces that, further to news releases dated April 13 and 23, 2021 and May 5, 2021, it has closed the second tranche of a non-brokered private placement of common units ("Common Units") and flow-through units ("Flow-Through Units") (the "Offering"). The Offering is a combination of (i) Common Units issued at a price of $0.15 per Common Unit and comprised of one (1) common share ("Common Share")  and one (1) Common Share purchase warrant, exercisable at $0.30 for

Calgary, Alberta - TheNewswire - May 17, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its fifth product, MultiXthick barium sulfate suspension that contains 105% w/v barium sulfate suspension for oral and rectal administration of the gastrointestinal tract.

Calgary, Alberta - TheNewswire - May 5, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its product, MultiXthin barium sulfate suspension. MultiXthin is specifically designed for single contrast radiographic examinations of the oesophagus, stomach, and small bowel to visualize the gastrointestinal (GI) tract in adult and pediatric patients.

Calgary, Alberta - TheNewswire - April 23, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has increased the previously announced non-brokered offering of units (the "Offering") from a maximum of $1,725,000 to $2,100,000.

Calgary, Alberta – TheNewswire - April 20, 2021 – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) USA (OTC:VYYRF) (the “Company” or “Voyageur”), is pleased to announce that the D.C. Circuit Court of Appeals

Calgary, Alberta – TheNewswire - April 13th 2021 – Voyageur Pharmaceuticals Ltd. (TSXV:VM) USA (OTC:VYYRF) (the “Company” or “Voyageur”), is pleased to announce a proposed non-brokered private placement financing of up to 11,500,000 units, for gross proceeds of up to $1,725,000 (the "Offering").  Under the Offering, the Company expects to raise up to $1,500,000, but has approved up to $1,725,000 to give the Company an option to increase the Offering by up to 15% to cover over-allocations, if any.  Pricing is as follows: A "Common Unit" priced at $0.15 where each Common Unit is comprised of on

Calgary, Alberta - TheNewswire - April 5th, 2021 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada (HC) for its product, MultiX barium sulfate powder. MultiX is specifically designed for oral suspension and indicated for use in single contrast radiographic examinations of the esophagus, stomach, duodenum and small bowel to visualize the gastrointestinal tract in adult and pediatric patients. Voyageur received 2 licenses for MultiX, one license for oral applications and one license for re

Calgary, Alberta – TheNewswire - April 5th, 2021 – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC:VYYRF) (the "Company" or "Voyageur")  announced that is has issued 2,625,000 options to directors, officers and consultants pursuant to its incentive stock option plan (the "Options").  On March 29, 2021, the Company's board of directors approved the grant of Options, to be effective on April 1, 2021 using the closing price on that day.  The Options were issued with an exercise price of $0.175 per common share, vest immediately, and have a 10 year term.  The Options are subject to regulatory and T

Calgary, Alberta - TheNewswire - March 10, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") announces that it has received $209,764.05 in cash proceeds from the exercise of previously issued warrants, finder's warrants and stock options. The proceeds will be allocated to continue to move the Company forward towards cash flow.  

Calgary, Alberta - TheNewswire - February 16, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada for its second product, HDXBa.   HDXBa is a barium radiographic contrast powder for suspension that is specifically formulated for Fluoroscopy barium X-Ray procedures and can also be used for CT Scans.   This approval authorizes the sale of HDXBa for use in radiology procedures in Canada.   HDXBa is specifically designed for X-Ray procedures of the entire upper and lower GI tract, includin

Calgary, Alberta – TheNewswire - February 12, 2021 – Voyageur Pharmaceuticals Ltd. (TSXV:VM) USA (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has received approval from Health Canada for SmoothX.   SmoothX is a barium radiographic contrast suspension that is specifically formulated for computed tomography procedures (CT Scans).   This approval authorizes the sale of SmoothX for use in radiology procedures in Canada.   SmoothX is specifically designed for use on CT Scans of the abdomen and gastrointestinal tract in both adults and pediatric patients.

Calgary, Alberta - TheNewswire - December January 15, 2021 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has completed the second and final closing of its previously announced non-brokered private placement of units (the "Offering").  The Company issued 4,300,000 Common Units (as defined below) in the second closing, resulting in a total number of 15,650,000 units being issued under the Offering, for total gross proceeds of $782,500, representing an increase of $82,500 to the maximum Offering amount previously announced.

Calgary, Alberta - TheNewswire - December 31, 2020 – Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce that it has increased the previously announced non-brokered offering of units (the "Offering") from a maximum of $600,000 to $700,000.  In addition, the Company announces that it has completed the first closing under the Offering by issuing 11,350,000 units for gross proceeds of $567,500.

Calgary, Alberta – TheNewswire - December 18, 2020 – Voyageur Pharmaceuticals Ltd. (TSXV:VM) USA (OTC:VYYRF) (the "Company" or "Voyageur") is please to announce the filing of its further updated Frances Creek Barite Project NI 43-101 Technical Report (the "Report") on SEDAR. The Report supersedes previous NI 43-101 reports filed by the Company on SEDAR and dated July 11, 2018 and February 7, 2019. The Report was co-authored by Craig Dunn, P. Geol. and Murray Lytle, Ph.D., P. Eng., is entitled "Technical Report: Voyageur Pharmaceuticals Ltd. Frances Creek Barite Early-Stage Exploration Project

Calgary, Alberta – TheNewswire - December 9th, 2020 – Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") is pleased to announce a proposed private placement of up to $600,000 of units (the "Offering"). The units shall be comprised of either: (i) one common share priced at $0.05 per unit and one common share purchase warrant of the Company, exercisable at $0.10 for two years from the closing date, and /or (ii) one Common Share issued on a flow-through basis pursuant to the Income Tax Act (Canada) priced at $0.05, and one half (1/2) (non-flow through) purchase war

Calgary, Alberta – TheNewswire - November 30, 2020 – Voyageur Pharmaceuticals Ltd. (TSXV:VM) USA (OTC:VYYRF) (the "Company" or "Voyageur") announces that it has signed a non-binding letter of intent with  Alberta Veterinarian Laboratories Ltd ("AVL") to manufacture barium radiographic contrast media for Voyageur. Voyageur and AVL will negotiate the terms of the definitive manufacturing contract and expect to have such contract in place in early 2021. AVL is an Alberta, family owned company that is led by Dr. Merle Olson.  Dr. Olson is a member of the board of directors of Voyageur. AVL is in

Calgary, Alberta – TheNewswire - November 18th, 2020 – Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the "Company" or "Voyageur") announces that it has formally withdrawn its 2017 corporate presentation titled "Voyageur Minerals Ltd. – Focussed on Critical & Strategic Minerals" (the "Presentation") and any guidance set out therein.  The Presentation was previously accessible on the Company's website and through LinkedIn.  Any reader who viewed the Presentation is cautioned not to place any reliance on the information contained therein.  In the Presentation, reference was made to th

Calgary, Alberta – TheNewswire - November 2, 2020 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the "Company" or "Voyageur") is pleased to announce the filing of its updated Frances Creek (FC) NI 43-101 Technical Report on SEDAR. Voyageur is working with SGS Canada Inc. (SGS) to complete a Preliminary Economic Assessment (PEA) and Pre-Feasibility (PF) study on its FC barium contrast project. SGS completed its site visit during the last week of October, 2020. This visit was a critical step forward in order to complete the PEA/Pre - Feasibility by  Q1 2021.

Calgary, Alberta – TheNewswire - July 27th, 2020 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the "Company" or "Voyageur") is pleased to announce the signing of a LOI with  THINQ Pharma-CRO Ltd (http://www.THINQcro.com/index.html), a pharmaceutical drug development and manufacturing company based in India. The LOI will be followed with a formal contract to engage THINQ for services for global regulatory consulting and management, generic drug and natural health product development and formulations, supply of iodine contrast’s active pharmaceutical ingredients; Iopamidol and iohexol to be used i

Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the “Company” or “Voyageur”) is pleased to announce it has signed an LOI with an established international mining company (the “Counterparty”) that has developed a low cost method to extract the...

CALGARY, Alberta – TheNewswire- April 3rd,2020 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the “Company” or “Voyageur”) (formally Voyageur Minerals Ltd.) is pleased to announce the filing of its 2019 year-end audited Financial Statements and MD&A. The Company's Financial Statements and MD&A are available on SEDAR (www.sedar.com).

CALGARY, Alberta - TheNewswire - March 27th, 2020 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”) (formally Voyageur Minerals Ltd.) announces the postponement of filing its annual financial statements (“Financial Statements”) and its annual management's discussion & analysis (“MD&A”) for the year ended November 30, 2019 due to logistics and delays caused by the COVID-19. Voyageur will invoke the Alberta Securities Commission (the “Commission”) blanket order 51-517 (the “Blanket Order”) for temporary exemption from certain corporate finance requireme

Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) is pleased to announce the dissolution of the current joint venture with Chief Medical Supplies (“Chief”).  Voyageur and Chief have worked together to create a new working...

Voyageur Pharmaceuticals Ltd. (TSX.V:VM, USA:VYYRF) (the “Company” or “Voyageur”) is pleased to announce the fully-integrated iodine business strategy which complements its ongoing barium contrast marketing strategy. Iodine contrast is one of...

Calgary, Alberta – TheNewswire - February 24th, 2020 – Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the “Company” or “Voyageur”) is pleased to announce the appointment of Ron Love, B.Comm, C.A.  as Chief Financial Officer.

Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the "Company" or "Voyageur") is implementing steps to ensure the Frances Creek barium sulfate project leads the industry in environmental best practices. Our objective is to create a project that has the...

Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the "Company" or "Voyageur") is pleased to announce successful test results by SGS Minerals & SGS Life Sciences division (“SGS”) on the Frances Creek barite project. SGS testing is a part of the ongoing...

Trent Abraham, Chairman of the Board of Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) is pleased to announce the appointment of Ron Sifton, ICD.D, CPA.CA, to the board of directors. Ron will also Chair the Audit Committee....

Dear Shareholders,

CALGARY, Alberta – TheNewswire - January 13th, 2020 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the “Company” or “Voyageur”) is pleased to announce the formulation and registration submission of Natural and Non Prescription Drug (NNHP) application to Health Canada for one additional radiographic product named MultiXthick.

CALGARY, Alberta – TheNewswire - January 10th, 2020, Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the “Company” or “Voyageur”) is pleased to announce the formulation and registration submission of Natural and Non Prescription Drug (NNHP) applications to Health Canada’s for one additional radiographic product named MultiXthin.

CALGARY, Alberta – TheNewswire - December 23, 2019 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC:VYYRF) (the “Company” or “Voyageur”) is pleased to report that it recently closed the third tranche of its previously announced private placement (the “Offering”), receiving aggregate gross proceeds of $95,100 from the issuance and sale of 1,268,000 units (“Units”) at a price of $0.075 per Unit. Each Unit consists of one common share and one common share purchase warrant (each, a “Warrant”) entitling the holder thereof to purchase one common share at an exercise price of $0.20 for a period of two

CALGARY, Alberta – TheNewswire - December 18th, 2019, Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the “Company” or “Voyageur”) has been working with SGS Canada to advance the  Frances Creek high purity barium sulfate project.  SGS Canada is currently working with the Frances Creek barite mineralized breccia and has successfully gravity separated a concentrated grade of 98.6% barium sulfate (4.4sg).  The samples have been sent to the pharmacy group at SGS for further testing and the results will be available in January. The next stage of the project will begin in January 2020 and will include the

Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to report that it recently closed the second tranche of its previously announced private placement (the “Offering”), receiving aggregate gross proceeds of $100,637.48 from...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) is pleased to announce that it has retained the services of Frontier Merchant Capital Group ("FronTier") to provide marketing and financial communications services.  FronTier is an...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) is pleased to announce the formulation and registration submission to Health Canada for its new drug product, MultiXBa. ImagingX Pharmaceuticals Ltd (“ImagingX”), a Voyageur...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) is pleased to announce that further to the news release dated October 4, 2019, Voyageur has mailed the notice of meeting and information circular to shareholders in connection with its...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) is pleased to announce the formulation and registration submission to Health Canada for its new drug product, HDXBa A total of two products have been submitted for registration with...

Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce a total closing of $401,155 dollars in flow through and equity units, including insider buying participation. $41,600 (520,000 units) of its non-brokered flow...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”). Voyageur is very pleased to announce that Brad Willis is being appointed to the Voyageur Board as a Director effective immediately.  Brad Willis is a founder of Voyageur Minerals and...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”). Voyageur is very pleased to announce that Dr. Merle Olson is being appointed to the Voyageur Board as a Director effective immediately. Dr. Olson has a Masters Degree in Chemistry...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) is pleased to announce that its joint venture company ImagingX Pharmaceuticals Ltd. (“ImagingX”) has submitted its first product for registration with Health Canada. Health Canada is a...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”). Voyageur is very pleased to announce that Mr. Randy Henkle is being appointed to the Voyageur Board as a Director effective immediately. Randy is a consultant geologist with over 45...

Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce the closing on July 23, 2019 of the first tranche of $260,000 (3,466,666 units) of its non-brokered private placement (“Private Placement”) announced on July 11,...

Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce that it is undertaking a non-brokered private placement of $400,000. The placement consists of units priced at $0.075 each, each unit consists of one share and...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) is pleased to announce the appointment of a new director and implementation of its succession plan for Voyageur’s CEO role. Effective July 1st, 2019, after four years of dedicated...

Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce the closing of the first tranche of $240,651.52 (3,210,687 units) of its non-brokered private placement (“Private Placement”) announced on April 25, 2019. After...

Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce that it is undertaking a non-brokered private placement of $400,000. The placement consists of units priced at $0.075 each, with each unit consists of 1 share...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) updates the progress on plans to produce a barium contrast product through its 50% owned joint venture, ImagingX Pharmaceutical Inc. (“ImagingX” or the “Joint Venture”).  The joint...

Voyageur Minerals Ltd. (TSXV: VM) (the "Company") is pleased to announce that it intends to extend the expiry date of 6,304,210 outstanding share purchase warrants ("Warrants") that are exercisable for common shares of the Company at $0.18 and...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”).  At the request of IIROC the Company wishes to clarify and retract certain disclosure in the news release disseminated by the Company on February 5, 2019.  Specifically: The news...

VANCOUVER, Feb. 8, 2019 /CNW/ - Trading resumes in:

VANCOUVER, Feb. 6, 2019 /CNW/ - The following issues have been halted by IIROC:

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) is pleased to announce that it has sent barite ore for testing to SGS Canada Inc. and to Allgaier Process Technology Inc. (“Allgaier”). A successful test using Allgaier’s density...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) is pleased to announce that it has applied for its bulk sample permit from the British Columbia Ministry of Mines. The 10,000 tonne bulk sample will be used for a major part of...

Voyageur Minerals Ltd. (TSX.V:VM) (the “Company” or “Voyageur”) is pleased to announce that it has created its new radiological contrast pharmaceutical joint venture company.   The company, named ImagingX Pharmaceuticals Inc. (“ImagingX”), is...

Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce that it has engaged Xnergy Financial Banking, of San Francisco, California and a member FINRA/SIPC to assist the Company in identifying institutional and other...

Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce that it has signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta. The joint venture will engage in the development, marketing...

Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce the closing of $188,412 private placement consisting of 2,512,166 equity units. After this issue, the Company will have 53,975,119 shares issued and outstanding....

Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce the closing of the second tranche of $251,337.50 consisting of 2,577,834 equity units, and 725,000 flow-through shares. After this issue, the Company will have...

Voyageur Minerals Ltd. (TSX-V: VM) (the "Company" or "Voyageur") is pleased to announce that the Company has signed a non-binding letter of intent (“LOI”) with Chief Medical Supplies Ltd. (“CMS” or “Chief”), which is a manufacturer, marketer, and...

Voyageur Minerals Ltd. (TSX-V:VM) (the "Company" or "Voyageur") is pleased to announce the results from the 2018 NI 43-101 on its 100% owned properties in British Columbia, Canada. The summary of barite resources contained in the Report are as...

Voyageur Minerals Ltd. (TSX-V:VM) (the "Company" or "Voyageur") is pleased to announce the results from the 2017 drilling program on its 100% owned Frances Creek barite project in British Columbia, Canada.  Barium contrast solutions, also...

Voyageur Minerals Ltd. (TSX-V:VM) (the “Company” or “Voyageur”) is pleased to announce the closing of the first tranche of $110,025 (1,467,000 units) of its non-brokered private placement announced on June 7, 2018. After this issue, the Company...

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2018) - Voyageur Minerals, (TSXV: VM), a Calgary based company which owns a 100% interest in three Barium Sulfate deposits, has announced a non-brokered private placement.

Voyageur Minerals Ltd. (TSXV:VM) (the “Company” or “Voyageur”) is pleased to announce that it is in the process of undertaking a non-brokered private placement of $500,000. The placement consists of units priced at $0.075 each, with each unit...

Calgary, Alberta / TheNewswire / May 8, 2018 – Voyageur Minerals Ltd. ("VM" or the “Company”) (TSX VENTURE:VM) is pleased to announce that it has signed a non-binding letter of intent (“LOI”) with Summit Nanotech Corporation (“SNC”), to develop proprietary processing technology for the production of high-purity lithium carbonate, magnesium carbonate, potassium carbonate, calcium carbonate and sodium carbonate from mineral brine waters. The technology is also envisioned to employ innovative carbon capture technology allowing VM to potentially capture CO2 from the atmosphere to be used in the p

Calgary, Alberta / TheNewswire / April 12, 2018 – Voyageur Minerals Ltd. (TSXV-VM) (the “Company” or “Voyageur”) is pleased to announce the closing of the first tranche of $126,911 (1,692,147 units) of its non-brokered private placement announced on March 7, 2018. After this issue, the Company will have 46,693,119 Shares issued and outstanding. Proceeds will be used for general working capital and to further the Company’s work program on its barite properties. Securities issued on this closing shall be subject to resale restrictions until August 13, 2018.

CALGARY, Alberta, March 20, 2018 (GLOBE NEWSWIRE) -- Voyageur Minerals Ltd. ("VM" or the “Company”) (TSX VENTURE:VM) is pleased to announce that it has signed a non-binding Memorandum of Understanding (“MOU”) with Innovation Metals Corp. (“IMC”), to access...

CALGARY, Alberta, March 06, 2018 (GLOBE NEWSWIRE) -- Voyageur Minerals Ltd. (TSX-V:VM) (the “Company” or “Voyageur”) is pleased to announce that it is in the process of undertaking a non-brokered private placement of $300,000.00.

CALGARY, Alberta, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Voyageur Minerals Ltd. (TSXV:VM) (the “Company” or “Voyageur”) is pleased to announce that in the last six months of 2017 the Company has raised a total of $539,629 for its...

CALGARY, Alberta, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Voyageur Minerals Ltd. (TSXV:VM) (the “Company”). is pleased to announce the results of the Company’s 2017 drilling program.  The Company completed 25 drill holes for a total of 1230.79m of...

CALGARY, Alberta, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Voyageur Minerals Ltd. (TSX-V:VM) (the “Company” or “Voyageur”) is undertaking a non–brokered private placement of up to 8,000,000 units of the Company (“Units”). As part of this financing the investor...

CALGARY, Alberta, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Voyageur Minerals Ltd. (TSXV:VM) (the “Company” or “Voyageur”) announces that it has closed the second tranche of a non–brokered private placement of 3,164,752 units of the Company (“Units”) at a...

CALGARY, Alberta, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Voyageur Minerals Ltd. (TSXV:VM) (the “Company”), is pleased to announce that it has completed the 2017 drilling program. Further laboratory results and project reports are pending.

CALGARY, Alberta, July 11, 2017 (GLOBE NEWSWIRE) -- Voyageur Minerals Ltd. (TSX-V:VM) (the “Company”), announces that drilling has commenced on its 100% owned Frances Creek industrial barite deposit. A 2000 meter drilling program will target two known zones of barite and will infill drill between these zones.  Over 2000m of historical drilling has been completed on this deposit....

VANCOUVER, March 6, 2017 /CNW/ - Trading resumes in: